UCLTF £1m investment into Quell Therapeutics is part of a £35m Series A round led by Syncona
The Series A round led by Syncona (with a commitment of £34m) set the company up with leading academic researchers from UCL, King’s College London and Hannover Medical School.
Quell has been established with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells that provide a regulatory function and have the ability to prevent unwanted over-activation of the immune system through their strong immune-suppressive capacity. Quell will seek to utilise the power of Treg cells to advance therapies for the management and treatment of a range of solid organ transplant and autoimmune conditions.
You can read the full article on the Investegate website.